Patient characteristics (N = 29)
| Parameter . | Value . |
|---|---|
| Median age at last follow-up, y (IQR, range) | 27 (24, 3-66) |
| Male sex, n (%) | 13 (45) |
| Ethnicity, n (%) | |
| White | 22 (76) |
| Arab | 4 (14) |
| Caribbean | 3 (10) |
| Median age at first TTP episode requiring FFP, y (IQR, range) | 11 (23, neonatal-32) |
| Neonatal jaundice and/or thrombocytopenia, n (%) | 11 (38) |
| Persistence of renal/neurological damage, n (%) | 3 (10) |
| Median total lifetime TTP episodes, n (IQR, range) | 5 (8, 1-60) |
| Multiple TTP episodes, n (%) | 23 (79) |
| Median annual rate of TTP episodes, n (IQR, range) | 0.28 (0.67, 0.03-4.00) |
| Regular FFP prophylaxis, n (%) | 12 (42) |
| Parameter . | Value . |
|---|---|
| Median age at last follow-up, y (IQR, range) | 27 (24, 3-66) |
| Male sex, n (%) | 13 (45) |
| Ethnicity, n (%) | |
| White | 22 (76) |
| Arab | 4 (14) |
| Caribbean | 3 (10) |
| Median age at first TTP episode requiring FFP, y (IQR, range) | 11 (23, neonatal-32) |
| Neonatal jaundice and/or thrombocytopenia, n (%) | 11 (38) |
| Persistence of renal/neurological damage, n (%) | 3 (10) |
| Median total lifetime TTP episodes, n (IQR, range) | 5 (8, 1-60) |
| Multiple TTP episodes, n (%) | 23 (79) |
| Median annual rate of TTP episodes, n (IQR, range) | 0.28 (0.67, 0.03-4.00) |
| Regular FFP prophylaxis, n (%) | 12 (42) |